

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Immunotech Biopharm Ltd

永泰生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6978)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 11 JANUARY 2023

The Board hereby announces that the proposed resolution as set out in the EGM Notice dated 16 December 2022 was duly passed by Shareholders at the EGM held on 11 January 2023 by way of poll.

Reference is made to the circular (the “**Circular**”) of Immunotech Biopharm Ltd (the “**Company**”) and the notice (the “**EGM Notice**”) of the Extraordinary General Meeting (the “**EGM**”) of the Company both dated 16 December 2022. Unless otherwise defined, the terms used in this announcement shall have the same meanings as those defined in the Circular and the EGM Notice.

POLL RESULTS OF THE EGM

As at the date of the EGM, the total number of Shares in issue was 514,584,000. As disclosed in the Circular, the Investor which was interested in 6,974,000 Shares, representing approximately 1.36% of the total number of issued Shares, had abstained from voting at the EGM as it has a material interest in the Subscription Agreement and the transactions contemplated thereunder. The total number of Shares entitling the Shareholders to attend and vote for or against the resolution proposed at the EGM was 507,610,000 Shares. Save as disclosed, there were no Shareholders who were entitled to attend the EGM but were required to abstain from voting in favour of the resolution proposed at the EGM as set out in Rule 13.40 of the Listing Rules. No Shareholders was entitled to attend and vote only against the resolution proposed at the EGM. No parties had stated their intention in the Circular to vote against or to abstain from voting on the resolution at the EGM.

The Board is pleased to announce that the proposed resolution as set out in the EGM Notice were duly passed by the Shareholders by way of poll at the EGM. The poll results of the resolution proposed at the EGM are as follows:

ORDINARY RESOLUTION*		Number of votes cast and approximate percentage of total number of votes	
		For	Against
1.	<p>(a) To approve the subscription agreement dated 28 October 2022 (the “Subscription Agreement”) in respect of the 11.75% secured convertible bonds due in 2025 in the aggregate principal amount of RMB300 million to be issued by the Company pursuant to the Subscription Agreement (the “Convertible Bonds”) and the transactions contemplated thereunder;</p> <p>(b) To approve the issue of Convertible Bonds;</p> <p>(c) To approve the allotment and issue of new ordinary shares of USD0.001 each in the share capital of the Company (the “Conversion Shares”);</p> <p>(d) To grant a specific mandate to the directors of the Company (the “Director(s)”) to exercise the powers of the Company for the issue of Convertible Bonds and the allotment and issue of the Conversion Shares; and</p> <p>(e) To authorise any one Director to do all such things and acts for the proposes of or in connection with the implementation of the Subscription Agreement and the transactions contemplated thereunder.</p>	<p>327,927,449 (86.44%)</p>	<p>51,458,400 (13.56%)</p>

* *The full text of the ordinary resolution is set out in the EGM Notice.*

Computershare Hong Kong Investor Services Limited, the Company’s Hong Kong Branch Share Registrar, acted as the scrutineer at the EGM for the purpose of vote-taking. As more than 50% of the votes were cast in favour of the above resolution, the resolution was duly passed as ordinary resolution at the EGM.

All of the Directors, namely Mr Tan Zheng, Dr Wang Yu, Mr Jung Hyun Chul, Mr Tao Ran, Mr Si Xiaobing, Mr Lu Yuan, Professor Wang Yingdian, Mr Ng Chi Kit and Ms Peng Sujiu, attended the EGM either in person or via electronic means.

By order of the Board
Immunotech Biopharm Ltd
Tan Zheng
Chairman and executive Director

Hong Kong, 11 January 2023

As at the date of this announcement, the Board comprises Mr Tan Zheng as Chairman and executive Director, Dr Wang Yu and Mr Jung Hyun Chul as executive Directors, Mr Tao Ran, Mr Si Xiaobing and Mr Lu Yuan as non-executive Directors, and Professor Wang Yingdian, Mr Ng Chi Kit and Ms Peng Sujiu as independent non-executive Directors.